Illumina, Inc. entered into a new $1,000 million senior unsecured five-year revolving credit facility on August 13, 2026, replacing its existing agreement dated January 4, 2023. The facility includes a $50 million swingline sublimit and a $75 million letter of credit sublimit, with an option to increase commitments or add term loans up to $500 million subject to lender consent. Interest rates are variable based on the SOFR or alternate base rate plus an applicable margin tied to the company's debt rating. The facility matures on August 13, 2031, with three one-year extension options, and contains standard financial covenants including a maximum total leverage ratio. No borrowings were outstanding as of the filing date. Illumina operates in the genomics industry, providing DNA sequencing and array-based technologies for life science research and clinical diagnostics.
